Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-16T22:23:11.526Z Has data issue: false hasContentIssue false
  • English
  • Français

Introduction

Published online by Cambridge University Press:  12 July 2012

Seol-Heui Han  and
Helen Lavretsky
Seol-Heui Han
Affiliation:
Department of Neurology, Konkuk University Medical Center, Seoul, Korea
Helen Lavretsky
Affiliation:
Department of Psychiatry and Biobehavoral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, Los Angeles, USA
Get access Rights & Permissions [Opens in a new window]

Extract

In June 2011, Dr. Willmar Schwabe Pharmaceuticals sponsored a two-day expert meeting in Amsterdam, The Netherlands. The meeting brought together 19 dementia experts from a range of disciplines and countries to review preclinical and clinical data on Ginkgo biloba special extract EGb 761® in the context of recent developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease (AD). Ginkgo biloba special extract EGb 761® is formally approved and reimbursed for the symptomatic treatment of age-related cognitive decline or dementia by numerous authorities worldwide. The meeting therefore focused on relevant research questions and potential study designs with appropriate target populations to prove the efficacy of Ginkgo biloba special extract EGb 761® as a disease-modifying product in AD and to reveal further relevant modes of action.

Type
Introduction
Information
International Psychogeriatrics , Volume 24 , Supplement S1: The aging brain: current concepts, intervention strategies and the role of Ginkgo biloba extract EGb 761 , August 2012 , pp. S1 - S2
Copyright
Copyright © International Psychogeriatric Association 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)